|
GSK PLC on Wednesday reported positive data for Arexvy, its respiratory syncytial virus vaccine for older adults. The Brentford, London-based pharmaceutical company said the results from the ongoing AReSVi-006 phase III trial showed vaccine efficacy against RSV-lower respiratory tract disease and severe disease over two full RSV seasons, including in participants with underlying medical conditions. The results indicated that one dose of the vaccine is effective against RSV-LRTD and severe LRTD over two full RSV seasons. The vaccine efficacy was estimated using a Poisson model adjusted by age, region and season. The firm said the clinical development programme will continue to evaluate longer term, and size up the optimal timing for potential revaccination. Chief Scientific Officer Tony Wood said: ‘Our goal is to provide a high level of protection for older adults most at risk from RSV. These data show the efficacy of a single dose of our vaccine over two RSV seasons against RSV-LRTD, including in the populations most at risk due to age or underlying medical conditions. This reinforces our confidence in its potential to make a significant public health impact.’ Regulatory probes for the vaccine in Japan and other nations are ongoing. The jab was approved by the European Commission earlier in June. GSK said the vaccine is not approved anywhere else in the world. RSV is a common contagious virus affecting the lungs and breathing passages. Shares were down 0.5% at 1,354.60 pence each on Wednesday morning in London. Copyright 2023 Alliance News Ltd. All Rights Reserved.
|
